Posted on

cbd for phantom pain

Cbd for phantom pain

It is also important to choose CBD products carefully and ensure they come from a reputable brand. Look for lab reports and read plenty of customer reviews before making a purchase. Taking this additional step will ensure the CBD is both safe and effective.

In this article, we explain the potential benefits of CBD for phantom limb pain and how to use it effectively.

Another way of using CBD, and one that may be especially useful for pain, is topical creams and ointments. It is possible to apply these products directly to an uncomfortable area, providing more targeted relief. The CBD enters the body through the top layer of skin, and many people report faster results in comparison to oral products.

On the other hand, CBD isolates contain no additional chemicals. This may be an advantage for anyone who undergoes regular drug testing and is concerned about traces of THC. Fortunately, there is now also a compromise between full-spectrum and CBD isolate. Broad-spectrum products offer a range of cannabinoids and terpenes, minus the THC.

Choosing the Best CBD Oil for Phantom Pain

In the past, many doctors believed that phantom pain was a psychological problem. However, recent discoveries suggest that it occurs due to the way the nervous system reorganizes itself after amputation.

CBD also has the advantage of coming from industrial hemp plants as well as cannabis. This feature means that CBD is far more widely available, even in many places without medical marijuana programs.

While CBD has many potential benefits, there are a few things to consider before using it for phantom pain.

What Is Phantom Pain?

Phantom pain may eventually resolve itself without treatment. However, in some cases, it persists for many years, significantly impacting a person’s quality of life.

Although there is no specific research on CBD for phantom pain, it may be worth a try. The compound has pain-relieving properties, is generally safe, and causes little in the way of side effects. However, there is a chance that CBD could interact with other drugs. For this reason, it is vital to consult a doctor before use.

Medical cannabis use is not like recreational consumption. Yes, I medicate with cannabis all day, every day. But I am rarely “high.” I take small amounts every few hours for pain control. Two years in, I take 70 percent fewer opiates than in 2016. I may never fully get off narcotics, but such a dramatic decrease has reduced their side effects.

In January 2006, when I was 29, I lost my left leg below the knee in a car accident. After months in a coma, I awoke to my brain fixating on the last signal from the now-missing limb: being crushed. Twelve years later, I still experience phantom pain – with very specific manifestations. I’ve wakened my husband more than once because my third metatarsal has shooting pain, or my heel is on fire, or my big toe is being crushed. But none of them are there. It’s disorienting and tormenting.

Cannabis is now medically or recreationally legal in 29 states and the District of Columbia. Ninety-one percent of Americans support legalizing medical marijuana, and 58 percent support legalizing recreational cannabis nationwide, even though cannabis remains federally illegal.

So, Do I Get High All Day?

A Foot No Longer There, a Pain That Never Leaves

There are several treatment options for phantom pain, including gabapentin (what I call the “workhorse” of my pain regimen), Lyrica, mirror therapy, cognitive-behavioral therapy, NSAIDs, biofeedback, hypnotism, acupuncture, surgery, and even ketamine infusions, but they all failed, adding to my despair.

In January 2016, days after medical marijuana became legal in the District of Columbia, my primary care physician advised me that he was enrolling me in the program, because he was tired of seeing me suffer. “The worst that’ll happen is you’ll get the munchies,” he laughed. “There’s anecdotal evidence that this can help. You’ve failed everything else, and cannabis can’t hurt; no one’s ever died from a cannabis overdose. It’s medicine, Meredith. Use it.”

Phantom pain results from psychogenic and physiological (mental and physical) activity and post-amputation changes in the residual limb and the brain. The prevalence of phantom pain in the first two years post-amputation is 65-80 percent; however, severe, chronic phantom pain past the second or third year affects only 5-10 percent of amputees.

An Ancient Cure: A Modern Option?

low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;

We anticipated that studies would use a variety of outcome measures, with most studies using standard subjective scales (numerical rating scale (NRS) or visual analogue scale (VAS) for pain intensity or pain relief, or both). We were particularly interested in Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) definitions for moderate and substantial benefit in chronic pain studies (Dworkin 2008).

Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study stated that outcome assessors were blinded to the intervention or exposure status of participants); unclear risk of bias (study stated that the outcome assessors were blinded but did not provide an adequate description of how it was achieved); high risk of bias (outcome assessors knew the intervention or exposure status of participants).

It is also hypothesised that cannabis reduces alterations in cognitive and autonomic processing in chronic pain states (Guindon 2009). The frontal‐limbic distribution of CB receptors in the brain suggests that cannabis may preferentially target the affective qualities of pain (Lee 2013). In addition, cannabis may attenuate low‐grade inflammation, another postulate for the pathogenesis of neuropathic pain (Zhang 2015).

Data synthesis

Withdrawals due to lack of efficacy;

Withdrawals due to adverse events (tolerability);

We selected randomised, double‐blind controlled trials of medical cannabis, plant‐derived and synthetic cannabis‐based medicines against placebo or any other active treatment of conditions with chronic neuropathic pain in adults, with a treatment duration of at least two weeks and at least 10 participants per treatment arm.

Types of outcome measures

Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk of bias (i.e. less than 10% of participants did not complete the study or used ‘baseline observation carried forward’ (BOCF) analysis, or both); unclear risk of bias (used ‘last observation carried forward’ analysis); or high risk of bias (used ‘completer’ analysis).

Two review authors (WH, FP) assessed the included studies using the Cochrane ‘Risk of bias’ tool. We defined studies with zero to two unclear or high risks of bias to be high‐quality studies, with three to five unclear or high risks of bias to be moderate‐quality studies, and with six to eight unclear or high risks of bias to be low‐quality studies (Schaefert 2015).